PMID- 35996165
OWN - NLM
STAT- MEDLINE
DCOM- 20220824
LR  - 20220826
IS  - 1757-2215 (Electronic)
IS  - 1757-2215 (Linking)
VI  - 15
IP  - 1
DP  - 2022 Aug 22
TI  - The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: 
      a meta‑analysis.
PG  - 99
LID - 10.1186/s13048-022-01028-7 [doi]
LID - 99
AB  - OBJECTIVE: To investigate the efficacy and safety of angiogenesis inhibitors in 
      the treatment of recurrent ovarian cancer (OC). METHODS: Electronic databases 
      including PubMed, Web of Science, and the Cochrane Library were searched to find 
      eligible studies until August 10, 2021. The data on overall survival (OS), 
      progression-free survival (PFS), and objective response rate (ORR) were pooled. 
      Furthermore, grade >/= 3 adverse events (AEs) were investigated. RESULTS: A total 
      of 13 studies with 3953 patients were included. Compared with control group, 
      angiogenesis inhibitors resulted in significant improvement in PFS (hazard ratio 
      (HR) = 0.61, 95%CI, 0.54-0.69), OS (HR = 0.88, 95%CI, 0.81-0.95), and ORR (odds 
      ratio (OR) = 2.15, 95% CI, 1.74-2.65). However, angiogenesis inhibitors were 
      associated with a higher risk of grade >/= 3 AEs (relative risk (RR), 1.20, 95% CI, 
      1.04-1.38). CONCLUSION: Angiogenesis inhibitors can improve ORR, PFS, and OS in 
      patients with recurrent OC, but they can increase the incidence of AEs >/= 3.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Chunmei
AU  - Zhang C
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, No. 36 Sanhao Street, Shenyang, Liaoning, 110004, China.
FAU - Zhao, Wancheng
AU  - Zhao W
AD  - Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical 
      University, No. 36 Sanhao Street, Shenyang, Liaoning, 110004, China. 
      373986045@qq.com.
LA  - eng
GR  - M0797/the internal fund of Shengjing Hospital of China Medical University/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20220822
PL  - England
TA  - J Ovarian Res
JT  - Journal of ovarian research
JID - 101474849
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - *Angiogenesis Inhibitors/adverse effects
MH  - Carcinoma, Ovarian Epithelial
MH  - Female
MH  - Humans
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Ovarian Neoplasms
PMC - PMC9396859
OTO - NOTNLM
OT  - Angiogenesis inhibitors
OT  - Objective response rate
OT  - Overall survival
OT  - Progression-free survival
OT  - Recurrent ovarian cancer
COIS- The authors declare that they have no competing interests.
EDAT- 2022/08/23 06:00
MHDA- 2022/08/25 06:00
PMCR- 2022/08/22
CRDT- 2022/08/22 23:41
PHST- 2021/10/08 00:00 [received]
PHST- 2022/08/03 00:00 [accepted]
PHST- 2022/08/22 23:41 [entrez]
PHST- 2022/08/23 06:00 [pubmed]
PHST- 2022/08/25 06:00 [medline]
PHST- 2022/08/22 00:00 [pmc-release]
AID - 10.1186/s13048-022-01028-7 [pii]
AID - 1028 [pii]
AID - 10.1186/s13048-022-01028-7 [doi]
PST - epublish
SO  - J Ovarian Res. 2022 Aug 22;15(1):99. doi: 10.1186/s13048-022-01028-7.